All In Biotech

Drug Trial Radar · NCT07104877

A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of SYH2051 in Combination With SYS6010 in Patients With Gastrointestinal Tumors Such as Advanced Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: Aug 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

25

Actual

Start

Apr 18, 2024

Primary completion

Nov 1, 2024

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Fujian Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, non-randomized trial design, including a dose escalation phase and a dose expansion phase, to evaluate the safety, tolerability and preliminary anti-tumor activity of SYS6010 in combination with SYH2051 in patients with advanced gastrointestinal tumors.

Conditions

  • Colorectal Cancer
  • Gastric Cancer (GC)
  • Gastrointestinal Tumors

Interventions

  • SYS6010Drug

    Administered via intravenous infusion at the dose of 3.2-4.8 mg/kg

  • SYH2051Drug

    Administered via oral at the dose of 40-80 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event (AE)Time frame: Up to 90 days following the last dose
  2. Dose-limiting toxicities (DLTs)Time frame: Up to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.